Orthopedic Surgery Doctors in Paterson, NJ Accepting Medicare

6 Orthopedic Surgery doctors found. Showing 1 - 6

Stephen Massood, M.D. Orthopaedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 703 Main St, St. Joseph's Regional Medical Center, Paterson, NJ 07503 Phone: 973-754-2270

Dr. Thomas Alexander Novack, M.D. Orthopaedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 703 Main St, Paterson, NJ 07503 Phone: 973-754-2000

Sina Pourtaheri, M.D. Orthopaedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 703 Main St, Paterson, NJ 07503 Phone: 973-754-2000

Alexander Decilveo, Orthopaedic Surgery - Sports Medicine Medicare: Not Enrolled in Medicare Practice Location: 703 Main St, Paterson, NJ 07503 Phone: 739-754-2000

Brandon Kevin Timur Rezzadeh, Orthopaedic Surgery - Orthopaedic Trauma Medicare: Not Enrolled in Medicare Practice Location: 703 Main St, Paterson, NJ 07503 Phone: 551-206-4444

Allan Strongwater, MD Orthopaedic Surgery - Pediatric Orthopaedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 703 Main St, St. Josephs Childrens Hospital, Paterson, NJ 07503 Phone: 917-757-3086

News Archive

New UM technology could provide five-minute diagnostic test and vaccine for Staph infections

New technology from the University of Maryland (UM) could potentially provide a five-minute diagnostic test and a vaccine for tough-to-treat Staphylococcus aureus infections, including the antibiotic-resistant MRSA, often called a "super bug," says inventor Mark Shirtliff, PhD, an associate professor at the UM School of Dentistry in Baltimore.

Vietnam asks for international help to tackle mystery skin disease

Vietnam has asked for international aid to get to the bottom of a mystery skin infection that has already killed 19 people. More than 170 people in the country's central province of Quang Ngai have reported symptoms reports say.

DURECT reports successful completion of DUR-928 Phase 1 study for acute use indications

DURECT Corporation today announced the successful completion of a Phase 1 clinical trial with an injectable formulation of DUR-928 intended for acute use indications. DUR-928 is an endogenous, small-molecule, new chemical entity (NCE), which may have broad applicability in metabolic diseases such as nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), and in acute organ injuries such as acute kidney injury (AKI).

Low-protein diet throughout pregnancy and lactation may increase risk of liver damage

A study in rats examines a pathway through which protein deficiency during pregnancy leads to fat accumulation in the liver and increased risk of liver damage.

Getting the word out when the need for speed is critical to public health

When the need for speed is critical, how can a public health department communicate with doctors and hospitals, sending alerts to help prevent or stop a public health crisis? How can thousands of health-care providers be notified about disease outbreaks, illness from food borne contaminants or even a possible pandemic?

Read more Medical News

› Verified 4 days ago